Get started
Author

Katy R. Newton

Observed names: K. Newton, KR Newton, Katy Newton, Katy R Newton, Newton, K, Newton, Katy R
OpenAlex ID: A5113438486
Interleukin‐17–producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers
2008 · Kiran Nistala, Halima Moncrieffe, et al. · Arthritis & Rheumatism · 332
PDF
International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: A tool for potential use in clinical trials
2007 · Lucy R. Wedderburn, Hemlata Varsani, et al. · Arthritis Care & Research · 172
Expression of the inflammatory chemokines CCL5, CCL3 and CXCL10 in juvenile idiopathic arthritis, and demonstration of CCL5 production by an atypical subset of CD8+ T cells
2006 · Daniel S Pharoah, Hemlata Varsani, et al. · Arthritis Research & Therapy · 68
PDF
Successful isolation and expansion of CMV ‐reactive T cells from G ‐ CSF mobilized donors that retain a strong cytotoxic effector function
2012 · Edward R. Samuel, Katy Newton, et al. · British Journal of Haematology · 16
Manufacture of GMP-compliant functional adenovirus-specific T-cell therapy for treatment of post-transplant infectious complications
2016 · Claire Horlock, Amanda Skulte, et al. · Cytotherapy · 13
Isolation of Highly Suppressive CD25+FoxP3+ T Regulatory Cells from G-CSF-Mobilized Donors with Retention of Cytotoxic Anti-Viral CTLs: Application for Multi-Functional Immunotherapy Post Stem Cell Transplantation
2014 · Edward R. Samuel, Lorea Beloki, et al. · PLoS ONE · 13
PDF
Human dendritic cells infected with an adenoviral vector suppress proliferation of autologous and allogeneic T cells
2008 · Katy R. Newton, Emma Sala‐Soriano, et al. · Immunology · 12
PDF
Quantification of normal range of inflammatory changes in morphologically normal pediatric muscle
2007 · Hemlata Varsani, Katy R. Newton, et al. · Muscle & Nerve · 10
CMV~IMPACT: Results of a Randomized Controlled Trial of Immuno-Prophylactic Adoptive Cellular Therapy following Sibling Donor Allogeneic HSCT
2014 · Karl S Peggs, Eleni Tholouli, et al. · Blood · 9
CMV-Specific T-Cell Therapy Improves Immune Reconstitution Following Unrelated Donor HSCT: Results of a Randomized Controlled Trial
2014 · Frederick Chen, Andrew Peniket, et al. · Transplantation and Cellular Therapy · 5
PDF
Abstract 875: Next generation clonal neoantigen targeting T cells, generated using the PELEUSTM bioinformatics platform and the VELOSTM manufacturing method show superior reactivity and phenotypic characteristics than classical TIL products
2020 · Eleni Kotsiou, Tie Zheng Hou, et al. · Cancer Research · 3
179P Early proof of concept of safety and clinical activity of clonal neoantigen-reactive T cells (cNeT)
2022 · M.D. Forster, J. Cave, et al. · Immuno-Oncology Technology · 2
437 Optimised achilles VELOSTM process 2b manufacturing platform generates a significant dose boost of reactive CD8 and CD4 clonal neoantigen-reactive T cells for the treatment of solid cancer
2023 · Monica Sassi, Sandro Gomez, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
543 Sensitive quantification and tracking of the active components of a Clonal Neoantigen T cell (cNeT) therapy: From manufacture to peripheral circulation
2021 · Samra Turajlic, Mariam Jamal-Hanjani, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
CMV-Reactive T Cells Can Be Isolated From G-CSF Mobilised Peripheral Blood Apheresates.
2010 · Edward R Samuel, Katy Newton, et al. · Blood · 1
1312 Identification and validation of immunogenic clonal neoantigens for personalized therapies
2023 · Gareth Wilson, Fong Chan, et al. · Journal for ImmunoTherapy of Cancer
PDF
193 The Achilles VELOSTM Process 2 boosts the dose of highly functional clonal neoantigen-reactive T cells for precision personalized cell therapies
2021 · Eleni Kotsiou, Joe Robinson, et al. · Journal for ImmunoTherapy of Cancer
PDF
Abstract CT054: The development of a personalized autologous clonal neoantigen T cell therapy for the treatment of solid cancer using the VELOSTM manufacturing platform generates highly potent and reactive CD8+ and CD4+ T cells for clinical use
2020 · Henrieta Fraser, Rebecca Pike, et al. · Cancer Research
Next generation clonal neoantigen targeting T cells, generated using the PELEUS (TM) bioinformatics platform and the VELOS (TM) manufacturing method show superior reactivity and phenotypic characteristics than classical TIL products
2020 · Eleni Kotsiou, Tz Hou, et al. · UCL Discovery (University College London)
The Impact of Donor HLA Type on Characteristics of CMV-Specific T Cell Products: Experience from Two UK Randomized Trials
2014 · Amanda Skulte, Arindam Mitra, et al. · Blood
Adenovirus (ADV) specific T cells (cytovir™ adv) developed as an advanced therapy medicinal product (ATMP), for the treatment of ADV infections following an allogeneic haematopoietic stem cell transplantat (allo-HSCT)
2014 · A. Stansfield, A. Mitra, et al. · Cytotherapy
Centralized production and distribution of CMV-specific cytotoxic T cell lymphocytes ready for commercialization
2013 · Katy Newton, Amanda Skulte, et al. · UCL Discovery (University College London)
Synovial fluid T cells are resistant to rAd based suppression of proliferation
2008 · Sala, E, Hunter, P, et al. · UCL Discovery (University College London)
IL-17-producing T cells are enriched in the joints of children with arthritis, and correlate with clinical phenotype
2008 · Kiran Nistala, Halima Moncrieffe, et al. · UCL Discovery (University College London)
Analysis of cellular and antibody responses to pneumococcal conjugate and polysaccharide vaccines
2007 · Keating, S, Johnson, M, et al. · UCL Discovery (University College London)
Works count: 37
Citation count: 658
H-index: 9
I10-index: 8
Year
Topic
Type